USP35 and cancer: Two studies demonstrated that USP35 deficiency sensitized cancer cells to cisplatin (the first platinum anti-cancer drug) treatment via de-stabilizing anti-apoptotic factor BIRC3 or activating cGAS-STING-TBK1-mediated expression of type I interferons [20, 23].